However, the ATTIRE trial which studied on the short-term use of albumin to increase the serum albumin level to a target of 30 g/l in hospitalized patient with decompensation cirrhosis failed to show superiority to standard treatment in terms of short-term risk of infection, kidney dysfunction and death. The gene discussed is ALB; the disease is Cirrhosis.